文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

妊娠合并SARS-CoV-2感染相关重症肺炎入住ICU的管理与结局:国际多中心COVIDPREG研究

Management and outcomes of pregnant women admitted to intensive care unit for severe pneumonia related to SARS-CoV-2 infection: the multicenter and international COVIDPREG study.
PubMed 文献 · Intensive Care Med · 2022-08-17
一句话结论妊娠合并COVID-19重症肺炎入住ICU者中39%需插管,肥胖、孕周增加、CT异常>50%及使用NIV是插管危险因素,37%在ICU期间分娩且分娩改善驱动压与氧合。

该回顾性多中心研究纳入法国、比利时和瑞士32个ICU的187例妊娠合并COVID-19入住ICU患者(33±6岁,孕28±7周),报告母体管理与母婴结局。41%患者仅用标准氧疗、29%仅用经鼻高流量氧疗、10%仅用无创通气,39%接受插管,8%需静脉-静脉体外膜氧合。多因素分析显示肥胖、孕周增加、CT异常范围>50%及使用NIV是插管的危险因素。37%患者在ICU期间因母体呼吸恶化需分娩,分娩改善驱动压和氧合;母体死亡率1%,胎儿/新生儿死亡率4%,母婴并发症发生率随呼吸支持侵入性增加而升高。

要点

  • 187例妊娠合并COVID-19入住ICU患者中73例(39%)接受插管,15例(8%)需静脉-静脉体外膜氧合。
  • 多因素分析插管危险因素:肥胖CSH 2.00(95%CI 1.05-3.80,p=0.03),孕周每增加1周CSH 1.07(95%CI 1.02-1.10,p=0.01),CT异常>50% CSH 2.69(95%CI 1.30-5.60,p<0.01),使用NIV CSH 2.06(95%CI 1.09-3.90,p=0.03)。
  • 70例(37%)在ICU期间需分娩,主要因母体呼吸恶化,分娩改善驱动压和氧合。
  • 72例(39%)需多种氧合技术,49例(26%)行清醒俯卧位或俯卧位。
  • 母体死亡率1%,胎儿/新生儿死亡率4%,母婴并发症发生率随母体呼吸支持侵入性增加而升高。

适用人群与场景

  • 法国、比利时和瑞士32个ICU收治的妊娠合并COVID-19入住ICU患者,共187例,年龄33±6岁,孕28±7周。
  • 76例(41%)肥胖,12例(6%)糖尿病,66例(35%)有妊娠相关并发症。

处置流程与药物剂量

  • 氧合支持:41例(22%)仅用标准氧疗,55例(29%)仅用经鼻高流量氧疗,18例(10%)仅用无创通气,73例(39%)插管,15例(8%)需静脉-静脉体外膜氧合。
  • 72例(39%)需多种氧合技术,49例(26%)行清醒俯卧位或俯卧位。
  • 157例(84%)使用糖皮质激素,25例(13%)使用托珠单抗。
  • 70例(37%)在ICU期间因母体呼吸恶化需分娩,分娩改善驱动压和氧合。

研究设计与关键结果

  • 回顾性多中心研究,32个ICU,纳入187例妊娠合并COVID-19入住ICU患者。
  • 插管危险因素多因素分析:肥胖CSH 2.00(95%CI 1.05-3.80,p=0.03);孕周每增加1周CSH 1.07(95%CI 1.02-1.10,p=0.01);CT异常范围>50% CSH 2.69(95%CI 1.30-5.60,p<0.01);使用NIV CSH 2.06(95%CI 1.09-3.90,p=0.03)。
  • 母体死亡率1%,胎儿/新生儿死亡率4%。
  • 母婴并发症发生率随母体呼吸支持侵入性增加而升高。

证据类型、等级与局限

  • 证据类型:回顾性多中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 妊娠合并COVID-19重症肺炎入住ICU时,肥胖、孕周增加、CT异常>50%及使用NIV提示插管风险升高,需密切监测。
  • ICU期间因母体呼吸恶化需分娩者占37%,分娩可改善驱动压和氧合。
  • 糖皮质激素、托珠单抗和俯卧位在妊娠患者中使用较少(分别为84%、13%、26%)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Management and outcomes of pregnant women with coronavirus disease 2019 (COVID-19) admitted to intensive care unit (ICU) remain to be investigated.

METHODS: A retrospective multicenter study conducted in 32 ICUs in France, Belgium and Switzerland. Maternal management as well as maternal and neonatal outcomes were reported.

RESULTS: Among the 187 pregnant women with COVID-19 (33 ± 6 years old and 28 ± 7 weeks' gestation), 76 (41%) were obese, 12 (6%) had diabetes mellitus and 66 (35%) had pregnancy-related complications. Standard oxygenation, high-flow nasal oxygen therapy (HFNO) and non-invasive ventilation (NIV) were used as the only oxygenation technique in 41 (22%), 55 (29%) and 18 (10%) patients, respectively, and 73 (39%) were intubated. Overall, 72 (39%) patients required several oxygenation techniques and 15 (8%) required venovenous extracorporeal membrane oxygenation. Corticosteroids and tocilizumab were administered in 157 (84%) and 25 (13%) patients, respectively. Awake prone positioning or prone positioning was performed in 49 (26%) patients. In multivariate analysis, risk factors for intubation were obesity (cause-specific hazard ratio (CSH) 2.00, 95% CI (1.05-3.80), p = 0.03), term of pregnancy (CSH 1.07, 95% CI (1.02-1.10), per + 1 week gestation, p = 0.01), extent of computed tomography (CT) scan abnormalities > 50% (CSH 2.69, 95% CI (1.30-5.60), p < 0.01) and NIV use (CSH 2.06, 95% CI (1.09-3.90), p = 0.03). Delivery was required during ICU stay in 70 (37%) patients, mainly due to maternal respiratory worsening, and improved the driving pressure and oxygenation. Maternal and fetal/neonatal mortality rates were 1% and 4%, respectively. The rate of maternal and/or neonatal complications increased with the invasiveness of maternal respiratory support.

CONCLUSION: In ICU, corticosteroids, tocilizumab and prone positioning were used in few pregnant women with COVID-19. Over a third of patients were intubated and delivery improved the driving pressure.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Péju E, Belicard F, Silva S, et al. Management and outcomes of pregnant women admitted to intensive care unit for severe pneumonia related to SARS-CoV-2 infection: the multicenter and international COVIDPREG study. Intensive Care Med. 2022. PMID: 35978137. doi:10.1007/s00134-022-06833-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。